Optimal Antiviral Prophylaxis Against Hepatitis B Reactivation in Patients Receiving Rituximab-Based Chemotherapy for Lymphoma

This publication has 16 references indexed in Scilit:

• Hepatitis B Reactivation in Patients With Previous Hepatitis B Virus Exposure Undergoing Rituximab-Containing Chemotherapy for Lymphoma: A Prospective Study
  Journal of Clinical Oncology, 2014
• Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: Analysis from the Asia Lymphoma Study Group
  European Journal of Cancer, 2013
• Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: A prospective study
  Hepatology, 2013
• Risk of hepatitis B virus (HBV) reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy: A meta-analysis
  Journal of Clinical Virology, 2013
• Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports
  Annals of Oncology, 2010
• Reactivation of hepatitis B virus after rituximab‐containing treatment in patients with CD20‐positive B‐cell lymphoma
  Cancer, 2010
• Hepatitis B Virus Reactivation in Lymphoma Patients With Prior Resolved Hepatitis B Undergoing Anticancer Therapy With or Without Rituximab
  Journal of Clinical Oncology, 2009
• Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach
  Blood, 2005
• Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy
  Gastroenterology, 2003
• Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: A prospective study of 626 patients with identification of risk factors
  Journal of Medical Virology, 2000